previously several years, the UK has witnessed a revolution in clinical body weight‑decline solutions — in the introduction of semaglutide (Wegovy®) for the developing acceptance of tirzepatide (Mounjaro®). Now, another title is drawing notice in the two scientific and community health circles: R